Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I skin safety study of SKE-18 1% cream in healthy Japanese males
jRCT2031230626Phase 1Completed
- Sponsor
- Sato Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of epinastine hydrochloride in rosacea (3 arms), sponsored by Sato Pharmaceutical. Primary endpoint: Safety. Started Mar 2024; status: completed.
02
Drugs
epinastine hydrochloride
03
Conditions
rosacea
Beyond the preview
Go deeper on jRCT2031230626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230626.